BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sutton EL. Profile of suvorexant in the management of insomnia. Drug Des Devel Ther 2015;9:6035-42. [PMID: 26648692 DOI: 10.2147/DDDT.S73224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Kazaglis L, Bornemann MAC. Classification of Parasomnias. Curr Sleep Medicine Rep 2016;2:45-52. [DOI: 10.1007/s40675-016-0039-y] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
3 Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Baldo BA. Prefrontal Cortical Opioids and Dysregulated Motivation: A Network Hypothesis. Trends Neurosci 2016;39:366-77. [PMID: 27233653 DOI: 10.1016/j.tins.2016.03.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
5 Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017;13:1289-99. [PMID: 29065953 DOI: 10.5664/jcsm.6800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
6 Hanazawa T, Kamijo Y. Effect of Suvorexant on Nocturnal Delirium in Elderly Patients with Alzheimer's Disease: A Case-series Study. Clin Psychopharmacol Neurosci 2019;17:547-50. [PMID: 31671494 DOI: 10.9758/cpn.2019.17.4.547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 Tabata H, Kuriyama A, Yamao F, Kitaguchi H, Shindo K. Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report. J Clin Sleep Med 2017;13:759-60. [PMID: 28212694 DOI: 10.5664/jcsm.6600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
8 Lv X, Pan J, Liu W, Meng X, Chen L, Zhou T, Lin K, Ye D, Zhou W. Identification, synthesis and strategy for minimization of potential impurities in the synthesis of suvorexant. Synthetic Communications 2021;51:2225-36. [DOI: 10.1080/00397911.2021.1930055] [Reference Citation Analysis]
9 Zou B, Cao WS, Guan Z, Xiao K, Pascual C, Xie J, Zhang J, Xie J, Kayser F, Lindsley CW, Weaver CD, Fang J, Xie XS. Direct activation of G-protein-gated inward rectifying K+ channels promotes nonrapid eye movement sleep. Sleep 2019;42:zsy244. [PMID: 30535004 DOI: 10.1093/sleep/zsy244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Maehara S, Yuge N, Higashi C, Ota T, Furukawa J, Takeuchi T. Pharmacological characterization of a novel potent, selective, and orally active orexin 2 receptor antagonist, SDM-878. Neuropsychopharmacol Rep 2020;40:182-9. [PMID: 32337858 DOI: 10.1002/npr2.12105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Heidbreder A, Dirks C, Ramm M. Therapy for Cataplexy. Curr Treat Options Neurol 2020;22. [DOI: 10.1007/s11940-020-0619-5] [Reference Citation Analysis]
12 Beuckmann CT, Ueno T, Nakagawa M, Suzuki M, Akasofu S. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 2019;42:zsz076. [PMID: 30923834 DOI: 10.1093/sleep/zsz076] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
13 Cabanas M, Pistono C, Puygrenier L, Rakesh D, Jeantet Y, Garret M, Cho YH. Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease. Neurotherapeutics 2019;16:784-96. [PMID: 30915710 DOI: 10.1007/s13311-019-00726-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
14 Toi N, Inaba M, Kurajoh M, Morioka T, Hayashi N, Hirota T, Miyaoka D, Emoto M, Yamada S. Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus. J Clin Transl Endocrinol 2019;15:37-44. [PMID: 30619717 DOI: 10.1016/j.jcte.2018.12.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]